|
Originally published In Press as doi:10.1074/jbc.M112473200 on February 20, 2002
J. Biol. Chem., Vol. 277, Issue 18, 15452-15458, May 3, 2002
Characterization of Dominant-negative Mutants of the DEAH-box
Splicing Factors Prp22 and Prp16*
Susanne
Schneider,
Hans-Rudolf
Hotz , and
Beate
Schwer§
From the Department of Microbiology and Immunology, Weill Medical
College of Cornell University, New York, New York 10021
Received for publication, December 31, 2001, and in revised form, February 12, 2002
 |
ABSTRACT |
Saccharomyces cerevisiae Prp22 and
Prp16 are RNA-dependent ATPases required for pre-mRNA
splicing. Both proteins are members of the DEXH-box family
of nucleic acid-dependent NTPases. Prior mutational
analysis of Prp22 and Prp16 identified residues within conserved motifs
I (GXGKT), II (DEAH), and VI
(QRXGRXGR) that are required for their
biological activity. Nonfunctional Prp22 and Prp16 mutants exerted a
dominant negative effect on cell growth. Here we show that
overexpression of lethal Prp22 mutants leads to accumulation of
unspliced pre-mRNAs and excised introns in vivo. The
biochemical basis for the lethality and inhibition of splicing in
vivo was determined by purifying and characterizing recombinant
mutant proteins. The lethal Prp22 mutants D603A and E604A in motif II
and Q804A and R808A in motif VI were defective for ATP hydrolysis and
mRNA release from the spliceosome, but were active in promoting
step 2 transesterification. Lethal Prp16 mutants G378A and K379A in
motif I; D473A and E474A in motif II; and Q685A, G688A, R689A, and
R692A in motif VI were defective for ATP hydrolysis and step 2 transesterification chemistry. The ATPase-defective mutants of Prp16
and Prp22 bound to spliceosomes in vitro and blocked the
function of the respective wild-type proteins in trans.
Comparing the mutational effects in Prp16 and Prp22 highlights
common as well as distinct structural requirements for the
ATP-dependent steps in pre-mRNA splicing.
 |
INTRODUCTION |
Nucleic acid-dependent NTPases of the
DEX(H/D)-box family play important roles in many biological
processes including transcription, DNA repair, and pre-mRNA
splicing. They use NTP hydrolysis to remodel macromolecular
interactions involving nucleic acids and proteins, and many of the
DEX(H/D)-box NTPases have RNA or DNA helicase activity
(1-3). DEX(H/D) proteins are defined by a set of collinear
motifs (1). The importance of individual residues for ATPase and/or
helicase activity has been demonstrated by mutational analysis of
several prototypal DEX(H/D) proteins (4, 5). Crystal
structures of the DEXH protein NS3 and other
DEX(H/D)-box NTPases show that conserved residues in the
motifs comprise the NTP binding site (2, 6-8).
The Saccharomyces cerevisiae genes PRP16 and
PRP22 encode essential splicing factors of the DEAH-box
family (9, 10). Prp16 is required for the second step of pre-mRNA
splicing, whereby the 3' splice site of the lariat-intermediate is
cleaved and the exons are joined (11). This was demonstrated by
in vitro reconstitution assays. In extracts depleted of
Prp16, spliceosomes assemble onto precursor RNA and catalyze 5' splice
site cleavage and formation of a branched lariat-intermediate. Purified
Prp16 can act on the step-arrested spliceosomes and trigger the
formation of mature RNA. Complementation of splicing requires ATP
hydrolysis by Prp16, which elicits a conformational change in the
spliceosome that can be measured as protection of the 3' splice
site against RNase H cleavage (12). The rearrangement that leads to 3'
splice site protection and mRNA formation requires the recruitment
of splicing factors Slu7, Prp18, and Prp22 (13-15). The role of Prp22
during the second step is independent of ATP. However, ATP is necessary for the function of Prp22 in catalyzing the release of mature RNA from
the spliceosome (15, 16).
We have undertaken a mutational analysis to evaluate the role of the
NTPase motifs of Prp16 and Prp22 in pre-mRNA splicing. Single
alanine mutations at conserved residues in motifs I (GKT), II (DEAH),
III (SAT), and VI (QRXGRXGR) were tested for
complementation of prp16 and prp22 deletion
strains. Most of the mutations were either lethal or caused conditional
growth defects. Overexpression of nonfunctional proteins led to
dominant-negative growth phenotypes in wild-type cells (17, 18).
Prior studies of Prp22 had focused on the analysis of cold-sensitive
Prp22 mutants H606A (motif II) and S635A and T637A (motif III) (18,
19). The S635A and T637A proteins retained full ATPase activity, but
were defective in catalyzing mRNA release in vitro and
failed to unwind RNA duplexes. Thus, ATPase activity was insufficient
for Prp22's function in mRNA release. It was proposed that Prp22
couples the energy of ATP hydrolysis to a conformational step, either
RNA unwinding or disruption of protein-RNA interactions (18). That the
ATPase activity of Prp22 was necessary for mRNA release was
inferred from an analysis of a mutant in which Lys-512 in motif I was
replaced by alanine; the K512A mutant was lethal, defective for ATP
hydrolysis and for mRNA release in vitro (15).
Here we address the following questions. 1) Does the correlation
between biological activity, ATPase activity, and splicing activity
pertain to other Prp22 mutants? 2) How do mutations in conserved
residues affect the ATPase and splicing function of Prp16? 3) Are
mutational effects concordant for Prp22 and Prp16? 4) Can the
mutational effects explain the dominant-negative effects on cell growth?
 |
EXPERIMENTAL PROCEDURES |
Expression and Purification of Recombinant
Prp22--
pET16b-based plasmids were constructed for the expression
of His-tagged Prp22 mutants D603A, E604A, Q804A, and R808A. The His10 tag does not interfere with the function of Prp22
in vivo, insofar as His-Prp22 complements a
prp22 strain. The expression plasmids were transformed
into Escherichia coli strain BL21-Codon Plus(DE3) RIL
(Stratagene). In parallel, we transformed with pET16b-PRP22 and
pET16b-K512A (15). The recombinant proteins were expressed and purified
from soluble bacterial lysates as described (18, 20).
Expression and Purification of Recombinant Prp16--
A DNA
fragment carrying the coding sequence of the PRP16 gene
(3278 bp) was ligated into the T7-based expression vector pET16b (Novagen). The pET16-PRP16 plasmid encodes a protein in which 10 histidines are fused in frame to the N terminus of Prp16. The His10 tag does not interfere with the function of Prp16
in vivo, insofar as His-Prp16 complements a
prp16 strain. Plasmids carrying mutant prp16
alleles were obtained by exchanging the corresponding mutated DNA
fragments from the p358-based PRP16 plasmids (17). E. coli
BL21(DE3) cells were transformed with the pET-PRP16 plasmids. Individual transformants were grown at 37 °C in LB medium containing 0.1 mg/ml ampicillin. When the A600 reached
0.6-0.7, the cultures were chilled on ice for 30 min. Sorbitol and
isopropyl-1-thio- -D-galactopyranoside were added to
final concentrations of 1 M and 0.5 mM,
respectively. The culture was incubated at 18 °C for 18 h.
Cells were harvested by centrifugation, and the cell pellets were
stored at 80 °C.
All subsequent operations were performed at 4 °C. Cell pellets from
3-liter cultures were suspended in 100 ml of lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM -mercaptoethanol, 10% sucrose). Lysozyme was added
to a final concentration of 0.2 mg/ml. After 30 min, the lysate was
adjusted to 0.1% Triton X-100. The lysate was sonicated to reduce
viscosity, and the insoluble material was removed by centrifugation at
38,000 × g for 30 min. The soluble lysate was adjusted
to 40% saturation with solid ammonium sulfate and then stirred for 30 min. The precipitate was collected by centrifugation and resuspended in
15 ml of buffer II (50 mM Tris-HCl, pH 7.6, 10% glycerol).
The protein solution was adjusted to 200 mM NaCl and 1 mM -mercaptoethanol and then mixed for 1 h with 3 ml (50% slurry) of nickel-nitrilotriacetic acid-agarose beads (Qiagen)
equilibrated in buffer III (50 mM Tris-HCl, pH 7.6, 250 mM NaCl, 1 mM -mercaptoethanol, 10%
glycerol). The mixture was poured into a column, washed with 20 ml of
35 mM imidazole in buffer III, and eluted with a 20-ml
linear gradient of 50-500 mM imidazole in buffer III.
Fractions of 1.2 ml were collected and their polypeptide compositions
were analyzed by SDS-PAGE. An aliquot of the peak fraction containing
recombinant Prp16 was diluted with buffer IV (20 mM
Tris-HCl, pH 7.6, 0.2 mM EDTA, 0.5 mM
dithiothreitol, 10% glycerol) to a final NaCl concentration of 30 mM, and loaded on a 1-ml DEAE-Sepharose CL-6B column
equilibrated with 30 mM NaCl in buffer IV. The column was
washed, and the adsorbed polypeptides were eluted with a 10-ml linear
gradient of 30-500 mM NaCl in buffer IV. The elution
profiles of recombinant Prp16 proteins were monitored by SDS-PAGE. The
protein concentrations in the DEAE fractions were measured using the
Bradford dye reagent (Bio-Rad) with bovine serum albumin as the standard.
ATPase Assays--
The ATPase activity of recombinant Prp16
proteins was measured using the conditions established for Prp16
proteins purified from yeast (21). Reaction mixtures (30 µl)
contained 50 mM triethanolamine, pH 8.2, 75 mM
potassium acetate, 1 mM dithiothreitol, 1.25 mM MgCl2, 0.5 mM [ -32P]ATP, 0.25 mM poly(A) (expressed as concentration of adenosine), and
increasing amounts of Prp16 proteins (90-360 ng) were incubated for 20 min at 23 °C. The reactions were stopped by the addition of 270 µl
of a 5% (w/v) suspension of activated charcoal in 20 mM
phosphoric acid. The samples were incubated on ice for 10 min, and the
charcoal was recovered by centrifugation. 32P radioactivity
in the supernatant was quantified by liquid scintillation counting. The
values represent averages from at least two independent experiments,
and the variation between experiments was below 10%.
The ATPase activity of Prp22 proteins was measured as described
(18-20). In brief, reaction mixtures (20 µl) containing 40 mM Tris-HCl, pH 8.0, 2 mM dithiothreitol, 2 mM MgCl2, 1 mM
[ -32P]ATP, 0.5 µg of poly(A) and Prp22 proteins as
indicated were incubated for 30 min at 30 °C. The reactions were
stopped by the addition of 200 µl of activated charcoal and processed
as described above. The results are average values from duplicate reactions.
In Vitro Pre-mRNA Splicing--
Yeast whole cell extract
from strain BJ2168 was prepared using the liquid nitrogen method (13).
The extract was immunodepleted of Prp22 using Prp22 affinity-purified
polyclonal antibodies as described (15, 18). Splicing reaction mixtures
(100 µl) contained 50% Prp22-depleted extract, ~400 fmol of
[32P]GMP-labeled actin precursor RNA, 60 mM
potassium phosphate, pH 7.0, 2.5 mM MgCl2, 2 mM ATP, and 3% polyethylene glycol 8000. The reaction
mixtures were incubated for 15 min at 23 °C, after which 50 ng of
wild-type or mutant Prp22 were added and incubation was continued for
10 min. The reaction mixtures were halted by transfer to ice. Aliquots
(90 µl) were layered onto 15-40% glycerol gradients containing 20 mM HEPES, pH 6.5, 100 mM KCl, 2 mM
EDTA. The gradients were centrifuged at 4 °C for 14 h at 35,000 rpm in a Sorvall TH641 rotor. Fractions (400 µl) were collected from the tops of the tubes. RNA was recovered from the gradient fractions by
phenol extraction and ethanol precipitation. RNAs from alternate fractions were analyzed by electrophoresis through a 6% polyacrylamide gel containing 7 M urea in 89 mM Tris borate, 2 mM EDTA. Radiolabeled RNA was visualized by
autoradiographic exposure of the dried gel. The amounts of the mRNA
products were quantified by scanning the gels using a STORM PhosphorImager.
RNA Analysis--
p133-PRP22 plasmids (TRP1 CEN)
carry wild-type Prp22 or the mutants K512A, D603A, and R808A under the
transcriptional control of the GAL1 promoter (18). The
plasmids were introduced into wild-type yeast cells. Trp+
transformants were selected and grown in glucose-containing synthetic medium (SD trp) at 30 °C to mid-logarithmic phase. Cells were recovered by centrifugation and suspended in SD trp medium containing either 2% glucose or 2% galactose. The cells in glucose medium were
harvested by centrifugation, washed in ice-cold water, and stored as
cell pellets at 80 °C. The cells in galactose-containing medium
were incubated for 12 h at 30 °C and then harvested. During the
incubation in galactose, the A600 of the culture
doubled for cells carrying the p133-PRP22 (wild-type
(WT)1) plasmid, but did not
increase for the cells bearing the mutant Prp22 plasmids. RNA was
isolated from thawed resuspended cells as described (22). The RNA was
ethanol-precipitated and resuspended in 10 mM Tris-HCl, pH
7.6, 1 mM EDTA. RNA concentration was calculated on the
basis of A260. Equivalent amounts (30 µg) of
total RNA of each sample were electrophoresed through a formaldehyde,
1% agarose gel. A radiolabeled RNA marker (RiboMark from Promega) was
co-electrophoresed. The gel was stained with ethidium bromide, photographed, and then transferred to a Hybond membrane
(Amersham Biosciences). Radiolabeled probes were prepared with a
random priming kit (Roche Molecular Biochemicals) according to the
vendor's instructions. Hybridization was performed as described
elsewhere (22); hybridized probes were visualized by autoradiography. Three identical blots were generated in parallel. These were first hybridized with probes for CYH2 and ACT1 (exon 2 probes) and for PGK1. The blots were then stripped by
boiling in hot water and re-probed with intron probes (CYH2,
ACT1, and SNR17A).
 |
RESULTS |
Effects of Prp22 Mutations on ATP Hydrolysis--
Conserved
residues in motifs I (511GKT), II (603DEAH),
and VI (804QRKGRAGR) are essential for the biological
function of Prp22; alanine substitutions for Lys-512, Asp-603, Glu-604,
Gln-804, and Arg-808 are lethal in vivo (18). To examine the
biochemical consequences of the lethal mutations, we produced
recombinant His10-tagged Prp22 proteins K512A (motif I),
D603A and E604A (motif II), Q804A and R808A (motif VI) and purified
them from soluble bacterial lysates by nickel-agarose affinity
chromatography, phosphocellulose chromatography, and glycerol gradient
sedimentation. The level of purity, as gauged by SDS-PAGE analysis, was
comparable for the five mutants and the wild-type Prp22 control (Fig.
1A; the Prp22 polypeptide is
denoted by an asterisk).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Mutational effects on Prp22 ATPase
activity. A, aliquots (0.5 µg) of the indicated
glycerol gradient preparations of Prp22 were analyzed by
electrophoresis in an 8% polyacrylamide gel containing 0.1% SDS.
Polypeptides were visualized by staining with Coomassie Blue dye. Prp22
is indicated by an asterisk. The positions and sizes (in
kDa) of marker proteins are indicated at the left.
B, the extents of ATP hydrolysis by wild-type Prp22 ( ),
R808A ( ), Q804A (*), K512A ( ), D603A ( ), and E604A (×) in the
presence of poly(A) are plotted as a function of input protein.
C, ATPase specific activities in the presence and absence of
poly(A) are expressed as turnover numbers (min 1).
|
|
The extent of ATP hydrolysis by wild-type Prp22 was proportional to
input protein (Fig. 1B); we calculated that Prp22 hydrolyzed 420 ATP min 1. The motif I K512A mutant hydrolyzed 20 ATP
min 1 (5% of wild type) (Fig. 1C). The motif
II mutant proteins D603A and E604A exhibited no activity (<0.5% of
wild type), whereas the motif VI mutants Q804A and R808A hydrolyzed 40 and 85 ATP min 1 (10 and 20% of wild type), respectively
(Fig. 1C). We infer that a threshold level of ATPase
activity is required for the in vivo function of Prp22.
Splicing Activity of ATPase-defective Prp22 Mutants--
Previous
work showed that the ATPase-defective mutant K512A supported mRNA
formation but not mRNA release (15). We now tested splicing
activity of the ATPase-defective mutants D603A, E604A, Q804A, and R808A
(Fig. 2). Splicing intermediates were
formed during a 15-min pre-incubation in extract immunodepleted of
Prp22. Aliquots of the reaction mixture were then supplemented with 50 ng of wild-type or mutant Prp22. Wild-type Prp22 and each of the mutants relieved the second step block and promoted the formation of
mature actin mRNA. However, excised lariat-intron accumulated in
reactions supplemented with each of the ATPase-defective Prp22 mutants,
but not in the wild-type Prp22 reactions, suggesting that spliceosome
disassembly was affected.

View larger version (90K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of Prp22 mutations on actin
pre-mRNA splicing in vitro. Spliceosomes were
formed on 32P-labeled actin pre-mRNA in extracts
depleted of Prp22 during a 15-min pre-incubation at 23 °C. Aliquots
of the reaction mixture were supplemented with buffer ( ) or 50 ng of
wild-type Prp22, D603A, E604A, K512A, Q804A, or R808A and then
incubated for 10 min at 30 °C. The reaction products were resolved
by denaturing PAGE followed by autoradiography. The symbols
at the left indicate the positions of the labeled RNA
species, which are (from top to bottom)
lariat-exon 2, intron-lariat, pre-mRNA, and spliced mRNA (exon
1 is not shown). Intron-lariat is indicated by an arrow at
the right.
|
|
To test directly whether the mutants catalyzed mRNA release from
the spliceosome, we analyzed the reaction products by glycerol gradient
sedimentation (Fig. 3). When the reaction
mixture was supplemented with wild-type Prp22, 85% of the mature
mRNA was released and sedimented near the top of the gradient
(fractions 7-13). In contrast, the Q804A mutant did not catalyze
mRNA release and 78% of the mRNA was found in the heavy
spliceosome peak (fractions 21-27). When the reactions were
supplemented with the K512A, D603A, E604A, and R808A mutants, 65, 61, 83, and 82% of the mature RNA was retained in the spliceosome
fractions, respectively (data not shown). Thus, the relevant defect of
the lethal Prp22 mutants with respect to splicing is their inability to
promote mRNA release from the spliceosome.

View larger version (132K):
[in this window]
[in a new window]
|
Fig. 3.
Release of mRNA from the
spliceosome. Spliceosomes that were formed in Prp22-depleted
extract were chased by the addition of recombinant WT or mutant (Q804A)
Prp22 proteins. The reaction mixtures were analyzed by zonal velocity
sedimentation. RNA was isolated from aliquots of the odd-numbered
fractions (fractions 3-29) of each glycerol gradient, analyzed by
denaturing PAGE and visualized by autoradiography. The arrow
indicates the position of mature mRNA. The amount of mRNA was
quantified using a PhosphorImager, and the sum of mRNA in all lanes
was set to 100%. Fractions 7-13 contained released mRNA, and
fractions 21-27 contained mRNA that was retained in the
spliceosome.
|
|
ATPase-defective Mutant Proteins Inhibit the Function of Wild-type
Prp22 in Vitro--
Lethal Prp22 mutants exert dominant-negative
effects when overexpressed in vivo (18). We tested whether
the ATPase-defective Q804A mutant inhibits the function of wild-type
Prp22 in vitro. Spliceosomes were formed in extracts
immunodepleted of Prp22. The reaction mixture was then supplemented
with wild-type and Q804A proteins pre-mixed at a ratio of either 1:1 or
1:10 (Fig. 4). Analysis of the splicing
products by glycerol gradient sedimentation showed that, when equal
amounts of wild-type and Q804A proteins were added, 68% of the mature
mRNA was released and 26% was retained in the spliceosome.
However, when Q804A was in 10-fold excess (500 ng) over wild-type Prp22
(50 ng), only 25% of mature mRNA was released and 71% was
retained (Fig. 4A). Similar experiments performed with
mutants E604A and R808A revealed that 10-fold excess of E604A and R808A
led to retention of 80 and 81% of the mature RNA in the spliceosome,
respectively (data not shown). Thus, excess mutant protein blocks the
function of wild-type Prp22 in vitro, providing a plausible
explanation for the dominant-negative phenotypes observed in
vivo.

View larger version (93K):
[in this window]
[in a new window]
|
Fig. 4.
Q804A inhibits release of mRNA by
wild-type Prp22. Spliceosomes were formed in extracts depleted of
Prp22. Aliquots of the reaction mixture were chased with 50 ng each of
WT and mutant Prp22 (Q804) (1:1) or with WT and Q804A proteins
pre-mixed at a ratio of 1:10 (50 ng of WT and 500 ng of Q804A). The
reaction mixtures were analyzed by zonal velocity sedimentation. RNA
was isolated from aliquots of the odd-numbered fractions of each
glycerol gradient, analyzed by denaturing PAGE, and visualized by
autoradiography. The amount of mRNA (indicated by arrow)
in each lane was quantified using a PhosphorImager. The sum of mRNA
in all lanes was set to 100%.
|
|
Previous studies showed that the K512A mutant remained associated with
the spliceosome after completion of step 2, i.e.
immunoprecipitation of the reaction products under native conditions
with Prp22-specific antibodies resulted in the recovery of mature
mRNA and lariat-intron, but not pre-mRNA (15). Here, using the
same immunoprecipitation assay, we found that the ATPase-defective
Prp22 mutants D603A, E604A, Q804A, and R808A also remained bound to the
spliceosomes after step 2 transesterification (data not shown). We
surmise that the ATPase-defective mutants inhibit wild-type Prp22
because they occupy a Prp22 binding site on the spliceosome, but do not function in spliceosome disassembly subsequent to their action in
forming mature mRNA.
Overexpression of Prp22 Mutants Results in a Splicing Defect in
Vivo--
The in vitro analysis (Fig. 4) would suggest that
overexpression of the nonfunctional Prp22 mutants in vivo
should elicit a splicing defect. To test this directly, we analyzed
RNAs from wild-type cells in which PRP22 or the
prp22 alleles K512A, D603A, or R808A were placed under the
transcriptional control of the GAL1 promoter. RNA was
isolated from the strains grown either in glucose-containing medium
(expression repressed) or in galactose-containing medium (expression
induced). Northern blots were probed for RNAs derived from the
ACT1, CYH2, and SNR17A (U3 small
nuclear RNA) genes (Fig. 5).
PGK1 RNA is not spliced and served as a loading control.
Hybridization to probes that specifically recognized intron sequences
showed the accumulation of CYH2 and of ACT1
pre-mRNA upon galactose-induced overexpression of K512A, D603A, and
R808A. Note that galactose-induced overexpression of wild-type
PRP22 did not lead to increased levels of pre-mRNA (Fig.
5, lane 5). The intron probe also detected the excised
intron RNA product of splicing of ACT1, CYH2, and
U3 (indicated by arrows in Fig. 5). The excised intron is
undetectable under normal circumstances (Fig. 5, lanes
1-5). Exon 2 probes were used to detect mRNA and pre-mRNA
of ACT1 and CYH2. Although low levels of
unspliced pre-CYH2 RNA were detectable in uninduced cells,
the galactose-induced overexpression of K512A, D603A, and
R808A resulted in the accumulation of unspliced pre-CYH2 RNA
(Fig. 5, lanes 6-8). We conclude that overexpression of
nonfunctional Prp22 mutants leads to a pre-mRNA splicing defect
in vivo. This defect, which is manifest in increased steady-state levels of pre-mRNA and of excised intron, is probably caused by the inhibition of spliceosome disassembly and subsequent recycling of splicing factors.

View larger version (88K):
[in this window]
[in a new window]
|
Fig. 5.
Northern blot analysis. RNA was isolated
from cells grown in either glucose (lanes 1-4) or galactose
(lanes 5-8) medium. Aliquots (30 µg) of total RNA were
separated on a 1% agarose/formaldehyde gel and then transferred to a
membrane, which was hybridized with denatured 32P-labeled
DNA fragments of the indicated genes. The blots were analyzed by
autoradiography. The left panel shows the
membranes after hybridization with probes that detect exon 2 plus
intron sequences. The relative levels of ACT1 pre-mRNA
are very low compared with ACT1 mRNA, so that precursor
RNA is not detectable on this exposure using the exon 2 probe. The
hybridization results using intron probes are shown in the
right panel. Asterisks (*)
indicate the position of precursor RNA, and arrows mark the
position of excised introns, deduced from co-electrophoresed RNA size
markers and the positions of ribosomal RNAs visualized with ethidium
bromide.
|
|
Effects of Prp16 Mutations on Pre-mRNA Splicing in
Vitro--
The DEAH-box ATPase Prp16 is required for the second step
of splicing. Prior mutational analysis identified 10 positions in the
NTPase motifs at which alanine substitutions abrogated Prp16 function
in vivo (17). These residues were Gly-378, Lys-379, and
Thr-380 in motif I (378GKT); Asp-473 and Glu-474 in motif
II (473DEAH); and Gln-685, Arg-686, Gly-688, Arg-689, and
Arg-692 in motif VI (685QRSGRAGR).
We next assessed the splicing activity of purified recombinant mutant
Prp16 proteins in vitro (Fig.
6). Yeast extracts immunodepleted of
Prp16 catalyzed the first step of splicing of pre-mRNA leading to
accumulation of exon 1 and lariat-exon 2 intermediate (11). The
pre-formed splicing intermediates could be readily chased into mature
RNA upon addition of 50 ng of wild-type Prp16 protein, but mutants
G378A, K379A, D473A, E474A, Q685A, G688A, R689A, and R692A were unable
to complement the step 2 defect (Fig. 6A).

View larger version (84K):
[in this window]
[in a new window]
|
Fig. 6.
Splicing activity of Prp16 proteins.
A, complementation of Prp16-depleted splicing extract with
wild-type and mutant proteins. Yeast whole cell extract was
immunodepleted of Prp16 and incubated with actin pre-mRNA for 20 min at 23 °C. Aliquots were supplemented with buffer ( ) and 50 ng
of each wild-type or mutant Prp16 proteins and incubated for another 10 min. B, inhibition of splicing by mutant Prp16 proteins.
Yeast whole cell extract was incubated with labeled actin pre-mRNA
and 50 ng of wild-type or mutant Prp16 polypeptides for 20 min at
23 °C. As a control, buffer ( ) was used instead of the protein
fraction. The RNA products were analyzed by denaturing PAGE and
autoradiography. The symbols at the left indicate
the positions of the labeled RNA species, which are (from
top to bottom) lariat-exon 2, intron-lariat,
pre-mRNA, spliced mRNA (note that exon 1 is not shown).
|
|
Step 2 complementation correlated with ATPase activity. In the linear
range of enzyme dependence, wild-type Prp16 hydrolyzed 270 ATP
min 1 in the presence of poly(A) (data not shown). The
Prp16 mutants that were nonfunctional in splicing had reduced ATPase
activity as follows: G378A (2% of wild type), K379A (9% of wild
type), D473A (1% of wild type), E474A (2% of wild type), Q685A (12%
of wild type), R689A (4% of wild type), and R692A (24% of wild type) (data not shown). These findings suggest that a threshold level of
ATPase activity ( 24% of wild type) is necessary for Prp16 function.
However, it is possible that ATPase activity is not sufficient for
Prp16 function and that the R692A mutant, which retains 24% of
wild-type activity, uncovers an additional requirement for motif VI in splicing.
Motif III Mutants of Prp16 Are Active in Pre-mRNA
Splicing--
Prp16 mutants S505A and T507A in motif III and H476A in
the DEAH-box (motif II) are functional in vivo (17). These
mutants are of particular interest in light of studies of NPH-II, NS3, and eIF-4A, which suggested that motif III and the
DEX(H/D)-box histidine/aspartate are responsible for
coupling NTP hydrolysis to RNA unwinding (23-25). Thus, we purified
the recombinant H476A, S505A, and T507A proteins and tested their
activity in vitro. H476A, S505A, and T507A supported step 2 transesterification in extracts immunodepleted of Prp16 (Fig.
6A). H476A, S505A, and T507A displayed 65, 71, and 34% of
wild-type ATPase activity, respectively. We conclude that the Ser and
Thr hydroxyls of motif III and the His in motif II are not essential
for Prp16 function in splicing in vitro, for ATP hydrolysis,
or for cell growth.
Prp16 Mutants Inhibit Splicing in Trans--
We noted previously
that overexpression of lethal Prp16 mutants blocked the growth of
wild-type yeast cells (17). Exogenous K379A mutant protein was shown to
inhibit splicing of actin pre-mRNA in whole cell lysates in
vitro (26). Here we tested whether other Prp16 mutants that were
inactive for splicing would affect splicing step 2 in the presence of
wild-type Prp16. Whole cell extract containing endogenous wild-type
Prp16 was supplemented with 50 ng of recombinant Prp16. Mature actin
mRNA was efficiently generated in unsupplemented mixtures, and
additional wild-type Prp16 had no impact on the reaction (Fig.
6B). The H476A, S505A, and T507A mutants also had no effect
on splicing. However, each of the eight mutant proteins that were
nonfunctional in complementing splicing in immunodepleted extracts were
inhibitory to splicing in extract containing Prp16. We surmise that the
G378A, K379A, D473A, E474A, Q685A, G688A, R689A, and R692A proteins can
bind to spliceosomes and thus block the function of wild-type Prp16 in
trans.
Mutant Prp16 Proteins Bind to Spliceosomes--
To determine
directly whether the Prp16 mutants bind to spliceosomes, we performed
immunoprecipitation experiments (Fig. 7). Because wild-type Prp16 had been shown to stably associate with spliceosomes only in the absence of ATP (11), we used an actin precursor RNA (C303/305) in which the 3' splice site is mutated. The 3'
splice site mutation in C303/305 precursor RNA does not interfere with
the first step of splicing, however, it effectively blocks step 2 chemistry (12, 27). C303/305 RNA was reacted with extract
immunodepleted of Prp16 to allow for spliceosome assembly and for the
first catalytic step to occur. Glucose was added to deplete ATP (by the
action of endogenous hexokinase), and then aliquots of the reaction
mixture were supplemented with Prp16 proteins in the absence or
presence of ATP. An aliquot (25%) of each reaction mixture served as
the input; the remainder (75%) was subjected to immunoprecipitation
with Prp16-specific antibodies (Fig. 7). As expected, wild-type Prp16
bound specifically to spliceosomes containing the RNA products of step
1 (but not precursor RNA) in the absence of ATP. However, the
association was destabilized upon ATP hydrolysis and only background
levels of RNAs were co-precipitated. In contrast, the K379A and R692A
mutants, which bound to spliceosomes in the absence of ATP, remained
stably associated in the presence of ATP. When similar experiments were
carried out with actin pre-mRNA, wild-type Prp16 promoted mRNA
formation and was released from the spliceosome. However, the Prp16
mutants K379A and R692A, and also G378A, D473A, E474A, Q685A, G688A,
and R689A, co-precipitated lariat-intermediates in the presence of ATP
(data not shown). These findings are consistent with the hypothesis
that ATPase-defective mutants block the function of wild-type Prp16
protein by occupying the Prp16 binding site on the spliceosome.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 7.
Binding of Prp16 to the spliceosome.
Mutated actin precursor RNA (C303/305) was incubated for 20 min in
extract depleted of Prp16. Glucose was then added to a final
concentration of 2.5 mM to allow for depletion of ATP by
endogenous hexokinase for 7 min. Aliquots were supplemented with
wild-type, K379A, or R692A proteins. As a control, buffer was used
instead of the protein fractions ( ). The reaction mixtures were
incubated for another 10 min either with ATP (5 mM final
concentration) or without addition of ATP. One quarter of each reaction
was analyzed by denaturing PAGE (INPUT), and three quarters
were used for immunoprecipitation with anti-Prp16 antibodies bound to
Protein A-Sepharose (IP -prp16). The RNA products were
analyzed by denaturing PAGE and autoradiography. The symbols
at the left indicate the positions of the labeled RNA
species. These are (from top to bottom)
lariat-exon 2, precursor RNA, and exon 1. The asterisk
indicates the 3' splice site mutation in C303/305 actin precursor
RNA.
|
|
 |
DISCUSSION |
We have conducted an inquiry into the basis for the lethality and
the dominant-negative phenotypes elicited by alanine substitutions in
motifs I, II, and VI of Prp16 and Prp22. The principle conclusion from
the in vitro analysis is that lethality arises from a defect in the execution of ATP-dependent steps in pre-mRNA
splicing, these being step 2 transesterification chemistry in the case
of Prp16 and the release of mature mRNA from the spliceosome in the case of Prp22. The dominant-negative inhibition of splicing can be
recapitulated in vitro for those Prp16 and Prp22 Ala mutants that inhibit cell growth when overexpressed in vivo. This
inhibition, together with direct studies of spliceosome binding by
immunoprecipitation, indicates that the splicing-defective Ala mutants
occupy specific sites on the spliceosome and thereby block the action
of the wild-type Prp16 and Prp22 proteins.
For mutations of the motif I lysine (GKT) and the Asp and
Glu in motif II (DEX(H/D), there is a clear
correlation between lethality and diminished ATPase activity.
Substitution of Asp and Glu by Ala abrogate ATP hydrolysis by both
Prp16 and Prp22. This is consistent with studies of other NTPases,
including vaccinia virus NPH-I and NPH-II, HCV NS3, and eIF-4A, which
show that the Asp and Glu residues are essential for ATP hydrolysis
(28-30). The motif II aspartic acid has also been replaced in yeast
Brr2 and Sub2, both of which play a role in spliceosome assembly (31, 32). In Brr2, replacing the aspartic acid in the DEIH-box by glycine
resulted in a protein that was nonfunctional in vivo and in vitro (31). A Sub2 mutant, in which motif II (DECD) was
changed to EECD, was lethal in vivo (32).
Mutation of the invariant lysine in motif I to alanine caused 10- and
20-fold decrements in the ATPase activities of Prp16 and Prp22. This is
again in agreement with other studies, although the magnitude of the
decrease in ATPase activity can vary between different NTPases. For
example, ATP hydrolysis by a motif I mutants of eIF-4A (Lys Asn
mutant) and of the Drosophila MLE (Lys Glu mutant) were
undetectable (23, 33). Alanine substitutions of the lysine in NPH-I and
NPH-II reduced ATPase activity by more than 10,000-fold in the case of
NPH-I and over 500-fold for NPH-II (24, 28). Replacing the motif I Lys
in HCV-NS3 by Ala caused a more modest reduction in the protein's
ATPase activity (4-5-fold) (30). Crystal structures of NTPases show
that the lysine of motif I contacts the - and -phosphates of the
bound nucleotide (2, 4).
Individual residues within motif VI are important for ATP hydrolysis by
eIF-4A, NS3, NPH-I, and NPH-II (28, 30, 34, 35). Structural studies
have suggested that motif VI is involved in nucleotide binding (2, 7).
Motif VI mutants of Prp16 and Prp22 are inactive in splicing; however,
they suffer a more modest decrement in ATPase activity than mutants in
motifs I and II. Does this indicate that splicing/viability requires a
threshold level of ATP hydrolysis that is above 20-24% of wild-type
activity for Prp22 and Prp16? Prior studies of several Prp16 mutants,
isolated in a genetic screen, suggest that low levels of ATPase
activity can suffice for function. Despite a 3-20-fold decrement in
ATP hydrolysis by those Prp16 mutants, which were purified from yeast, the Prp16 mutants did not exhibit any splicing or growth defect in vivo (36). It is possible that the lack of a tight
correlation between lethality and ATPase activity hints at a more
complex role for motif VI in splicing that is not limited to ATP
hydrolysis. Alternatively, the requirements for ATP hydrolysis by Prp16
and Prp22 in the context of the spliceosome may differ from those of
the isolated enzymes.
A difference between Prp16 and Prp22 that is reinforced in
the current study concerns the function of the hydroxyls of the serine/threonine residues in motif III (SAT) and the histidine in the
DEXH-box. Alanine substitutions at these positions in Prp16 resulted in proteins that were functional in splicing in
vitro and in vivo. This is in contrast to the findings
for Prp22 and for vaccinia virus NPH-II. Alanine substitutions at the
His residue in the DEXH-box or either of the threonines in
motif III (TAT) of NPH-II were lethal in vivo (24). The
NPH-II mutants retained ATPase activity, but were unable to unwind an
RNA duplex in vitro, suggesting uncoupling of ATPase and
helicase activity (24, 29). The Prp22 mutants H606A (motif II) and
S635A and T637A (motif III) retained ATPase activity, but showed severe
growth phenotypes, e.g. S635A failed to grow at temperatures
<34 °C (18). The growth phenotype reflects the deficiency of the
Prp22 mutants in releasing mature mRNA from the spliceosome (18,
19). Notably, both Prp22 motif III mutants also uncoupled ATP
hydrolysis from RNA unwinding (18).
It is thought that Prp16 and Prp22 disrupt or remodel macromolecular
contacts within the spliceosome, which may involve RNA/RNA, protein/RNA, or protein/protein interactions. The distinct molecular phenotypes exhibited by motif III Ala mutants may indicate a difference in the nature of the rearrangements triggered by Prp22 and Prp16.
Conserved ATPase motifs are important for Prp16 and Prp22's function
in splicing; however, they are not involved in spliceosome binding.
Nonfunctional Prp16 and Prp22 mutants elicit dominant-negative effects,
presumably by occupying binding sites on the spliceosome and thus
blocking access by the respective wild-type protein.
Dominant-negative phenotypes have been described for numerous mutants
in DEX(H/D)-box splicing factors, including Prp2, Brr2, and
Sub2 (32, 31, 37, 38). The biochemical analysis of dominant-negative
Prp2 mutants showed that, although many of the mutant proteins bound to
the spliceosome and blocked the function of wild-type Prp2 in
vitro, the nonfunctional Prp2 mutant H349K (in motif II) was
dominant-negative in vivo, but failed to bind to
spliceosomes or to inhibit splicing by wild-type Prp2 in
vitro (37). Thus, dominant-negative effects do not inevitably
arise from binding of a nonfunctional DEX(H/D)-box
protein to the spliceosome.
It is also not axiomatic that all inactivating mutations in the ATPase
domain of DEX(H/D)-box splicing factors elicit
dominant-negative phenotypes, as might be suggested by studies of
mutants of Prp16, Prp22, Prp2, and Brr2 (21, 31, 37, 38). For example,
lethal mutants in motifs I (GKT GNT) and II (DECD EECD) of Sub2
did not inhibit growth of wild-type cells (32). However, the Sub2-LAT mutant (in motif III) exhibits dominant-negative effects upon overexpression. Because motifs I and II are implicated in nucleotide binding, whereas motif III is not, it is possible that only Sub2 mutants that can bind ATP elicit dominant-negative phenotypes.
 |
ACKNOWLEDGEMENT |
The Department of Microbiology and Immunology
gratefully acknowledges the support of the William Randolph Hearst Foundation.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant GM50288.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Wellcome Trust Sanger Inst., Hinxton, Cambridge
CB10 1SA, United Kingdom.
§
To whom correspondence should be addressed. Tel.: 212-746-6518;
Fax: 212-746-8587; E-mail:
bschwer@mail.med.cornell.edu.
Published, JBC Papers in Press, February 20, 2002, DOI 10.1074/jbc.M112473200
 |
ABBREVIATIONS |
The abbreviation used is:
WT, wild-type.
 |
REFERENCES |
| 1.
|
de la Cruz, J.,
Kressler, D.,
and Linder, P.
(1999)
Trends Biochem. Sci.
24,
192-198[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Tanner, N. K.,
and Linder, P.
(2001)
Mol. Cell
8,
251-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Schwer, B.
(2001)
Nat. Struct. Biol.
8,
113-116[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Hall, M. C.,
and Matson, S. W.
(1999)
Mol. Microbiol.
34,
867-877[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Linder, P.,
Gasteiger, E.,
and Bairoch, A.
(2000)
Yeast
16,
507-509[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Yao, N.,
Hesson, T.,
Cable, M.,
Hong, Z.,
Kwong, A. D., Le, H. V.,
and Weber, P. C.
(1997)
Nat. Struct. Biol.
4,
463-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Kim, J. L.,
Morgenstern, K. A.,
Griffith, J. P.,
Dwyer, M. D.,
Thomson, J. A.,
Murcko, M. A.,
Lin, C.,
and Caron, P. R.
(1998)
Structure
6,
89-100[Medline]
[Order article via Infotrieve]
|
| 8.
|
Cho, H.-S., Ha, N.-C.,
Kang, L.-W.,
Chung, K. M.,
Back, S. H.,
Jang, S. K.,
and Oh, B. H.
(1998)
J. Biol. Chem.
273,
15045-15052[Abstract/Free Full Text]
|
| 9.
|
Company, M.,
Arenas, J.,
and Abelson, J.
(1991)
Nature
349,
487-493[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Burgess, S.,
Couto, J. R.,
and Guthrie, C.
(1990)
Cell
60,
705-717[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Schwer, B.,
and Guthrie, C.
(1991)
Nature
349,
494-499[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Schwer, B.,
and Guthrie, C.
(1992)
EMBO J.
11,
5033-5039[Medline]
[Order article via Infotrieve]
|
| 13.
|
Ansari, A.,
and Schwer, B.
(1994)
EMBO J.
14,
4001-4009
|
| 14.
|
Zhang, X.,
and Schwer, B.
(1997)
Nucleic Acids Res.
25,
2146-2152[Abstract/Free Full Text]
|
| 15.
|
Schwer, B.,
and Gross, C. H.
(1998)
EMBO J.
17,
2086-2094[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Wagner, J. D. O.,
Jankowsky, E.,
Company, M.,
Pyle, A. M.,
and Abelson, J. N.
(1998)
EMBO J.
17,
2926-2937[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Hotz, H. R.,
and Schwer, B.
(1998)
Genetics
149,
807-814[Abstract/Free Full Text]
|
| 18.
|
Schwer, B.,
and Meszaros, T.
(2000)
EMBO J.
19,
6582-6591[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Campodonico, E.,
and Schwer, B.
(2002)
Genetics
160,
407-415[Abstract/Free Full Text]
|
| 20.
|
Schneider, S.,
and Schwer, B.
(2001)
J. Biol. Chem.
276,
21184-21191[Abstract/Free Full Text]
|
| 21.
|
Schwer, B.,
and Guthrie, C.
(1992)
Mol. Cell. Biol.
12,
3540-3547[Abstract/Free Full Text]
|
| 22.
|
Herrick, D.,
Parker, R.,
and Jacobsen, A.
(1990)
Mol. Cell. Biol.
10,
2269-2284[Abstract/Free Full Text]
|
| 23.
|
Pause, A.,
and Sonenberg, N.
(1992)
EMBO J.
11,
2643-2654[Medline]
[Order article via Infotrieve]
|
| 24.
|
Gross, C. H.,
and Shuman, S.
(1998)
J. Virol.
72,
4729-4736[Abstract/Free Full Text]
|
| 25.
|
Heilek, G. M.,
and Peterson, M. G.
(1997)
J. Virol.
71,
6264-6266[Abstract]
|
| 26.
|
Chanfreau, G.,
Gouyette, C.,
Schwer, B.,
and Jacquier, A.
(1999)
RNA
5,
876-882[Abstract]
|
| 27.
|
Vijayraghavan, U.,
Parker, R.,
Tamm, J.,
Iimura, Y.,
Rossi, J.,
Abelson, J.,
and Guthrie, J.
(1986)
EMBO J.
5,
1683-1695[Medline]
[Order article via Infotrieve]
|
| 28.
|
Martins, A.,
Gross, C. H.,
and Shuman, S.
(1999)
J. Virol.
73,
1302-1308[Abstract/Free Full Text]
|
| 29.
|
Gross, C. H.,
and Shuman, S.
(1995)
J. Virol.
69,
4727-4736[Abstract]
|
| 30.
|
Wardell, A. D.,
Errington, W.,
Ciaramella, G.,
Merson, J.,
and McGarvey, M. J.
(1999)
J. Gen. Virol.
80,
701-709[Abstract]
|
| 31.
|
Kim, D. H.,
and Rossi, J. J.
(1999)
RNA
5,
959-971[Abstract]
|
| 32.
|
Zhang, M.,
and Green, M.
(2001)
Genes Dev.
15,
30-35[Abstract/Free Full Text]
|
| 33.
|
Lee, C. G.,
Chang, K. A.,
Kuroda, M.,
and Hurwitz, J.
(1997)
EMBO J.
16,
2671-2681[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Pause, A.,
Methot, N.,
and Sonenberg, N.
(1993)
Mol. Cell. Biol.
13,
6789-6798[Abstract/Free Full Text]
|
| 35.
|
Gross, C. H.,
and Shuman, S.
(1996)
J. Virol.
70,
1706-1713[Abstract]
|
| 36.
|
Burgess, S. M.,
and Guthrie, C.
(1993)
Cell
73,
1377-1391[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Edwalds-Gilbert, G.,
Kim, D.-H.,
Kim, S.-H.,
Tseng, Y.-H., Yu, Y.,
and Lin, R. J.
(2000)
RNA
6,
1106-1119[Abstract]
|
| 38.
|
Plumpton, M.,
McGarvey, M.,
and Beggs, J. D.
(1994)
EMBO J.
13,
879-887[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Ungar, N. Yosef, Y. Sela, R. Sharan, E. Ruppin, and M. Kupiec
A genome-wide screen for essential yeast genes that affect telomere length maintenance
Nucleic Acids Res.,
July 1, 2009;
37(12):
3840 - 3849.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Chalupnikova, S. Lattmann, N. Selak, F. Iwamoto, Y. Fujiki, and Y. Nagamine
Recruitment of the RNA Helicase RHAU to Stress Granules via a Unique RNA-binding Domain
J. Biol. Chem.,
December 12, 2008;
283(50):
35186 - 35198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Andersen and N. Tapon
Drosophila MFAP1 Is Required for Pre-mRNA Processing and G2/M Progression
J. Biol. Chem.,
November 7, 2008;
283(45):
31256 - 31267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. S. Elles and O. C. Uhlenbeck
Mutation of the arginine finger in the active site of Escherichia coli DbpA abolishes ATPase and helicase activity and confers a dominant slow growth phenotype
Nucleic Acids Res.,
January 17, 2008;
36(1):
41 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Aronova, D. Bacikova, L. B. Crotti, D. S. Horowitz, and B. Schwer
Functional interactions between Prp8, Prp18, Slu7, and U5 snRNA during the second step of pre-mRNA splicing
RNA,
September 1, 2007;
13(9):
1437 - 1444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Zhang and A. R. Krainer
Splicing remodels messenger ribonucleoprotein architecture via eIF4A3-dependent and -independent recruitment of exon junction complex components
PNAS,
July 10, 2007;
104(28):
11574 - 11579.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Bowers, P. A. Maroney, M. E. Fairman, B. Kastner, R. Luhrmann, T. W. Nilsen, and E. Jankowsky
Discriminatory RNP remodeling by the DEAD-box protein DED1
RNA,
May 1, 2006;
12(5):
903 - 912.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Granneman, K. A. Bernstein, F. Bleichert, and S. J. Baserga
Comprehensive Mutational Analysis of Yeast DEXD/H Box RNA Helicases Required for Small Ribosomal Subunit Synthesis
Mol. Cell. Biol.,
February 15, 2006;
26(4):
1183 - 1194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. GRAINGER and J. D. BEGGS
Prp8 protein: At the heart of the spliceosome
RNA,
May 1, 2005;
11(5):
533 - 557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Rocak, B. Emery, N. K. Tanner, and P. Linder
Characterization of the ATPase and unwinding activities of the yeast DEAD-box protein Has1p and the analysis of the roles of the conserved motifs
Nucleic Acids Res.,
February 17, 2005;
33(3):
999 - 1009.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Schneider, E. Campodonico, and B. Schwer
Motifs IV and V in the DEAH Box Splicing Factor Prp22 Are Important for RNA Unwinding, and Helicase-defective Prp22 Mutants Are Suppressed by Prp8
J. Biol. Chem.,
March 5, 2004;
279(10):
8617 - 8626.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. EDWALDS-GILBERT, D.-H. KIM, E. SILVERMAN, and R.-J. LIN
Definition of a spliceosome interaction domain in yeast Prp2 ATPase
RNA,
February 1, 2004;
10(2):
210 - 220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Perriman, I. Barta, G. K. Voeltz, J. Abelson, and M. Ares Jr.
ATP requirement for Prp5p function is determined by Cus2p and the structure of U2 small nuclear RNA
PNAS,
November 25, 2003;
100(24):
13857 - 13862.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|